SEC Form 4 · accession 0001104659-18-025639
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Victor Vaughn
Officer — Sr. VP of Sales & Marketing
Period of report
Apr 18, 2018
Accepted (ET)
Apr 20, 2018 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 18, 2018 | M | 6,250 | $12.98 | A | 15,594 | D | |
| Common Stock | Apr 18, 2018 | M | 3,750 | $25.30 | A | 19,344 | D | |
| Common StockF2 | Apr 18, 2018 | S | 10,000 | $47.0617 | D | 9,344 | D | |
| Common Stock | Apr 19, 2018 | M | 7,850 | $25.30 | A | 17,194 | D | |
| Common StockF3 | Apr 19, 2018 | S | 7,850 | $49.0261 | D | 9,344 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $12.98 | Apr 18, 2018 | M | 6,250 | D | — | Mar 1, 2026 | Common Stock | 6,250 | 25,000 | D |
| Employee Stock Option (Right to Buy)F5 | $25.30 | Apr 18, 2018 | M | 3,750 | D | — | Feb 24, 2027 | Common Stock | 3,750 | 46,250 | D |
| Employee Stock Option (Right to Buy)F5 | $25.30 | Apr 19, 2018 | M | 7,850 | D | — | Feb 24, 2027 | Common Stock | 7,850 | 38,400 | D |
Explanation of responses
- F1Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.15, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted.
- F5The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted.